BSc3094
Modify Date: 2025-08-27 09:42:42
BSc3094 structure
|
Common Name | BSc3094 | ||
|---|---|---|---|---|
| CAS Number | 946857-84-7 | Molecular Weight | 380.38100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H12N6O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BSc3094BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD)[1]. |
| Name | N'-(4-(4-nitrophenyl)thiazol-2-yl)-1H-benzo[d]imidazole-6-carbohydrazide |
|---|
| Description | BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD)[1]. |
|---|---|
| Related Catalog | |
| Target |
Tau aggregation[1] |
| In Vivo | BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau[1]. BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%[1]. BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice[1]. Animal Model: Mice[1] Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice[1] Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%. |
| References |
| Molecular Formula | C17H12N6O3S |
|---|---|
| Molecular Weight | 380.38100 |
| Exact Mass | 380.06900 |
| PSA | 156.76000 |
| LogP | 4.33860 |
| Hazard Codes | Xi |
|---|